|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nisoldipine#Patient Counseling Information]] |
| {{Nisoldipine}}
| |
| {{CMG}}; {{AE}}:{{AK}}
| |
| | |
| '''''For patient information about Nisoldipine, click [[Nisoldipine (patient information)|here]].'''''
| |
| | |
| ==Information for Patients==
| |
| | |
| SULAR is an extended release tablet and should be swallowed whole. Tablets should not be chewed, divided or crushed. SULAR should be taken on an empty stomach (1 hour before or 2 hours after a meal). Grapefruit juice, which has been shown to increase significantly the bioavailability of nisoldipine and other [[dihydropyridine]] type calcium channel blockers, should not be taken with SULAR.
| |
| | |
| This product contains FD&C Yellow No. 5 ([[tartrazine]]) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
| |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |